Qian Guo1,2,3Liancheng Zhu1Caixia Wang1Shuang Wang1Xin Nie1Juanjuan Liu1Qing Liu1Yingying Hao1Xiao Li1Bei Lin1,2,3*1Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China2Key Laboratory of Maternal-Fetal Medicine of Liaoning Province, Benxi, China3Key Laboratory of Obstetrics and Gynecology of Higher Education of Liaoning Province, Benxi, China

In the published article, there was an error in Figure 2B as published. The image for panel (8) was incorrectly placed, resulting in a repetition of the image for panel (7). Consequently, both panels (7) and (8) show the OVCAR3 transwell image, while the OVCAR3-SERPIND1-L-Mock transwell image was not included in the correct position. The correct content should have panel (7) showing the OVCAR3 transwell image and panel (8) showing the blank control OVCAR3-SERPIND1-L-Mock transwell image. This was entirely an inadvertent error due to the similar naming of the images, leading to the incorrect image being used. The corrected Figure 2B and its caption appear below.

Figure 2. Effects of SERPIND1 on ovarian cancer cells in vitro. (A) SERPIND1 promoted the migration capacity of ovarian cancer cells. (B) SERPIND1 promoted the invasion capacity of ovarian cancer cells. (C) SERPIND1 inhibited apoptosis in ovarian cancer cell lines. (D) Effects of SERPIND1 on the cell cycle of ovarian cancer cell lines. (E) SERPIND1 promoted the proliferation of ovarian cancer cells. (1): ES-2; (2): ES-2-SERPIND1-H-Mock; (3): ES-2-SERPIND1-H; (4): CAOV3; (5): CAOV3-SERPIND1-L- Mock; (6): CAOV3-SERPIND1-L; (7): OVCAR3; (8): OVCAR3-SERPIND1-L- Mock (9): OVCAR3-SERPIND1-L. Data are presented as mean ± standard deviation from three independent experiments. *P < 0.05. Scale bar: 100 μm. SERPIND1, serpin family D member 1.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: epithelial ovarian cancer, SERPIND1, prognosis, proliferation, cell cycle, cell migration, EMT, NF-κB1

Citation: Guo Q, Zhu L, Wang C, Wang S, Nie X, Liu J, Liu Q, Hao Y, Li X and Lin B (2024) Corrigendum: SERPIND1 affects the malignant biological behavior of epithelial ovarian cancer via the PI3K/AKT pathway: a mechanistic study. Front. Oncol. 14:1466959. doi: 10.3389/fonc.2024.1466959

Received: 18 July 2024; Accepted: 04 November 2024;
Published: 03 December 2024.

Edited and Reviewed by:

Luisa Lanfrancone, European Institute of Oncology (IEO), Italy

Copyright © 2024 Guo, Zhu, Wang, Wang, Nie, Liu, Liu, Hao, Li and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Bei Lin, bGluYmVpODhAaG90bWFpbC5jb20=; cHJvZl9saW5iZWlAMTI2LmNvbQ==